CAMBRIDGE, Mass. — Aug 4, 2026 — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative study in the journal npj Precision Oncology . The peer-reviewed paper demonstrates how advanced artificial intelligence combined with comprehensive multi-omic analysis can successfully identify promising therapeutic targets in one of the rarest and least understood forms of head and neck cancer.
The study represents the first comprehensive molecular characterization of inverted papilloma-associated sinonasal squamous cell carcinoma (IP-SNSCC). Conducted with leading investigators from the University of Chicago and Johns Hopkins University, the research illustrates how AI-powered biological target discovery can generate actionable therapeutic hypotheses even when conventional research is constrained by small patient populations and scarce molecular data.
By integrating whole-exome sequencing, RNA sequencing, mitochondrial DNA sequencing, and AI-driven target prioritization, the research team reconstructed the molecular evolution of disease progression while identifying potential therapeutic opportunities for future clinical investigation.
"Rare cancers have historically suffered from limited molecular data and few opportunities for therapeutic discovery," said Alex Zhavoronkov, PhD , Founder and CEO of Insilico Medicine and co-corresponding author of the study. "By combining comprehensive multi-omic profiling with PandaOmics, we were able to generate actionable therapeutic hypotheses in a disease where conventional approaches have struggled. This study demonstrates how AI can accelerate the identification of novel biology and potential therapeutic targets, helping researchers move from molecular understanding toward translational opportunities—even in diseases that have received relatively little attention."
IP-SNSCC represents an incredibly rare and aggressive subset of head and neck cancers that develops through the malignant transformation of benign inverted papillomas. Despite aggressive surgery and radiation therapy, patients face highly limited treatment options, and almost no targeted therapies exist due to the extreme scarcity of clinical data.
To map how the disease progresses, researchers analyzed matched normal tissue, benign papilloma, and invasive carcinoma samples. Rather than discovering a single dominant genetic mutation, the integrated genomic and transcriptomic analysis revealed a coordinated cascade of biological changes that accompany the transition to invasive cancer, including:
These findings provide the scientific community with its first comprehensive molecular atlas of IP-SNSCC, establishing an essential framework for future translational research.
To translate these raw biological findings into treatment strategies, the investigators utilized PandaOmics® , Insilico Medicine’s proprietary AI-powered target discovery platform.
Using its advanced TargetID algorithms, PandaOmics integrated the study's transcriptomic data with pathway biology, protein interaction networks, genetic evidence, and druggability assessments. The AI platform successfully prioritized:
While additional experimental and clinical validation are required, the results demonstrate a scalable framework for accelerating drug discovery across a wide range of rare diseases where patient cohorts are too small for traditional research models.
The study, titled "Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma-associated sinonasal squamous cell carcinoma," is available online in npj Precision Oncology https://doi.org/10.1038/s41698-026-01599-4
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, HKEX:3696.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.
npj Precision Oncology
Comprehensive multi-omic dissection and AI-prioritized target identification in inverted papilloma–associated sinonasal squamous cell carcinoma
10-Jul-2026